CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

Allied Esports Entertainment Inc

American Resources Corp

Immutep Ltd

Cenntro Electric Group

Super League Gaming Inc

Uranium Energy

Reddit penny stocks are full of risk and reward, which is why $100 won't hurt you, but it can reward you handsomely. The post 7 Reddit Penny Stocks to Buy if You Have $100 to Spare appeared first on InvestorPlace.

7 Reddit Penny Stocks to Buy if You Have $100 to Spare

SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET. The conference will be held in a virtual meeting format.

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2021 Results - Earnings Call Transcript

SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2021. "The U.S. Food and Drug Administration's (FDA) acceptance of our New Drug Application (NDA) for pacritinib with priority review and a Prescription Drug User Fee Act (PDUFA) action date of November 30, 2021 brings us one step closer to providing pacritinib to myelofibrosis patients with severe thrombocytopenia who are underserved by existing therapies," said Adam R.

CTI BioPharma Reports First Quarter 2021 Financial Results

The FDA has accepted for review CTI BioPharma Corp's (NASDAQ: CTIC) marketing application seeking approval for pacritinib in myelofibrosis patients with severe thrombocytopenia (low platelet count). Under the Priority Review, the agency's target action date is November 30, 2021.

CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer

SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L), with the NDA being granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is November 30, 2021.

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

Aikido Pharma Inc.

Actinium Pharmaceuticals

Atossa Genetics

Bionano Genomics

Onconova Therapeutics

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.

7 Reddit Penny Stocks Promising to Cure Cancer

SEATTLE, May 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m.

CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021

Abeona Therapeutics

Energy Focus

Fortress Biotech

ION Geophysical

Pixelworks

Synlogic

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

7 Penny Stocks That May Not Be Penny Stocks For Long

SEATTLE, April 7, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14

CTI BioPharma's (NASDAQ:CTIC) stock has been falling Thursday, down 13.06% to a price of $2.55. Thursday the stock has been traded at a volume of 2.13 million, about 326.0% of its recent 30-day volume average of 654.29 thousand.

Why CTI BioPharma's Stock is Down During Today's Session

The stock price of CTI BioPharma Corp (NASDAQ: CTIC) fell by over 10% pre-market. This is why it happened.

CTI BioPharma Stock Price Fell Over 10% Pre-Market: Why It Happened

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced the pricing of its previously announced underwritten public offering of 14,260,800 shares of its common stock and 600 shares of its series X1 preferred stock (the "Series X1 Preferred"). In addition, CTI has granted the underwriters a 30-day option to purchase up to an additional 2,139,120 shares of its common stock on the same terms and conditions.

CTI BioPharma Corp. Announces Pricing of its Public Offering of Common Stock and Preferred Stock

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced that it intends to offer and sell shares of its common stock and series X1 preferred stock (the "Series X1 Preferred") in an underwritten registered public offering. All of the securities in the proposed offering are to be sold by CTI.

CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock and Preferred Stock

CTI BioPharma Corp (NASDAQ: CTIC) has completed a rolling marketing application submission to the FDA seeking approval of pacritinib for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L). CTIC had previously announced the results of a pre-NDA meeting wherein an agreement was reached on the submission package to be based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 trials.

CTI BioPharma Stock Is Trading Higher On Complete Submission For Rolling Pacritinib US Application

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ("NDA") submission to the U.S. Food and Drug Administration ("FDA") seeking approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L). CTI had previously announced the results of a pre-NDA meeting with FDA where agreement was reached on an NDA submission package based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 trials.

CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp (NASDAQ: CTIC) has announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study evaluating pacritinib, to prevent acute graft-versus-host disease (GVHD). Pacritinib showed an encouraging safety profile and exhibited preliminary therapeutic activity in preventing acute GVHD after allogeneic hematopoietic cell transplantation.

CTI BioPharma's Pacritinib Demonstrates Positive Safety Profile In Graft-Versus-Host-Disease Study

SEATTLE, March 22, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), today announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study led by Joseph Pidala, MD, PhD (Moffitt Cancer Center), and Brian C. Betts, MD (Masonic Cancer Center at the University of Minnesota), evaluating pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, for the prevention of acute graft-versus-host disease (GVHD).

Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer Research

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q4 2020 Results - Earnings Call Transcript

SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020. "This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow for the potential U.S. approval and commercial launch of pacritinib in 2021," said Adam R.

CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results

SEATTLE, March 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m.

CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

Today, we take our first in depth look at CTI BioPharma, that looks like it might finally garner its first FDA approval.

CTI BioPharma: Potential Light At End Of The Rainbow

AquaBounty Technologies

iBio

Alpine Immune Sciences

These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020

SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format. Presentation details: Event: The...

CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15

CTIC recently received FDA's accelerated approval go-ahead for pacritinib in MF patients with severe thrombocytopenia. This considerably reduces the risks associated with the company.

News for CTI BioPharma Stock (CTIC)